Western Suburbs Cancer Clinical Trials

Cancer Clinical Trials

Western Suburbs Cancer Clinical Trials

If you or someone you love is facing cancer, clinical trials may provide an alternative. Northwestern Medicine offers clinical studies right in your community for a wide variety of types and stages of cancer. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease.

Clinical trials have played an important role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than current treatments. Most of the approaches that doctors use to treat cancer today would never have become available without clinical trials.

Current Central DuPage Hospital, Delnor Hospital and Kishwaukee Hospital Cancer Clinical Trials

Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Central DuPage HospitalNorthwestern Medicine Delnor Hospital and Northwestern Medicine Kishwaukee Hospital. For ease of searching, the trials are sorted into the following categories:

  • Bladder
  • Blood, Bone & Tissue
  • Brain
  • Breast
  • Colorectal
  • Esophageal
  • Head and Neck
  • Gastrointestinal
  • Kidney
  • Liver
  • Lung
  • Pancreatic
  • Prostate
  • Women's Reproductive System
  • Other Cancers

If you find a clinical trial that interests you, talk with your physician or call 630.933.6528. TTY for the hearing impaired 630.933.4833.

View Trials

Study: Chemoradiotherapy with or w/o Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer.
Clinical Trial #: S1806
NCT Number: NCT03775265
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov


Study: (PREVAIL) A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma
Clinical Trial #: D419BR00008
NCT Number: NCT03788746
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov


Study: (AMBASSADOR) Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma vs Observation.
Clinical Trial #: A031501
NCT Number: NCT03244384
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Clinical Trial #: S1608
NCT Number: NCT03269669
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
Clinical Trial #: DCL-16-001
NCT Number: NCT02952508
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Clinical Trial #: EA9161
NCT Number: NCT03701282
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: A randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Clinical Trial #: EA4151
NCT Number: NCT03267433
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: A Randomized Phase III Sudy of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years or Age) with Chronic Lymphocytic Leukemia (CLL)
Clinical Trial #: A041702
NCT Number: NCT03737981
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: Molecular Analysis for Therapy Choice (MATCH) for Patients with histologically documented solid tumors and lymphomas
Clinical Trial #: EAY131 (Match)
NCT Number: NCT02465060
Principal Investigator: Michael Kahn, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: Randomized Phase II/III study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Clinical Trial #: A051701
NCT Number: NCT03984448
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: A Randomized 3- Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A)in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma
Clinical Trial #: EA4181
NCT Number: NCT04115631
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Clinical Trial #: A221602
NCT Number: NCT03578081
Principal Investigator: Christopher George, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609 - DART
NCT Number: NCT02834013
Principal Investigator: Christopher George, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Clinical Trial #: EAA173
NCT Number: NCT03937635
Principal Investigator: Dr. Eisner
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 


Study: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Clinical Trial #: S1826
NCT Number: NCT03907488
Principal Investigator: Dr. Eisner
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

 

Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
NCT #: NCT02179086
Principal Investigator: Vinai Gondi, MD1
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG-CC003
NCT #: NCT02635009
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Phase II, single arm, open label trial combining Optune with concurrent Bevacizumab or Progressive Meningioma
Clinical Trial #: NU16C02
NCT #: NCT02847559
Principal Investigator: Dr. Grimm
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577 (CODEL)
NCT #: NCT00887146
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Phase III< Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy.
Clinical Trial #: Orbus, STELLAR Study OT-15-001
NCT #: NCT02796261
Principal Investigator: Dr. Grimm
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Pivotal, open label, randomized study of radiosurgery with or without Tumor Treating Fields for 1-10 brain metastases from non-small cell lung cancer.
Clinical Trial #: NovoCure METIS EF-25
NCT #: NCT02831959
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Molecular Analysis for Therapy Choice (MATCH) for Patients with histologically documented solid tumors and lymphomas
Clinical Trial #: EAY131
NCT #: NCT02465060
Principal Investigator: Dr. Kahn
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
NCT #: NCT02834013
Principal Investigator: Dr. George
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Serum Lactate: a potential biomarker for malignant primary brain tumors and differentiator for tumor recurrence vs. radiation necrosis
Clinical Trial #: 17-049
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Nervous System Tumor Bank
Clinical Trial #: 17-048
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Cerebrovascular Tumor Bank
Clinical Trial #: 17-063
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Detection of altered cognition in brain disease via assessment of speech abnormalities as assessed by novel verbal linguistic analysis software.
Clinical Trial #: 18-046
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2

Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Clinical Trial #: NU 15B06
NCT Number: NCT02694809
Principal Investigator: Mary Ahn, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Clinical Trial #: Prelude DCISionRT
NCT Number: NCT03448926
Principal Investigator: Christy Kesslering, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: RT CHARM: PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION
Clinical Trial #: A221505 (CHARM)
NCT Number: NCT03414970
Principal Investigator: Christy Kesslering, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
Clinical Trial #: S1418/NRG-BR006
NCT Number: NCT02954874
Principal Investigator: John Ayers, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER (BWEL)
Clinical Trial #: A011401
NCT Number: NCT02750826
Principal Investigator: John Ayers, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
Clinical Trial #: A011502
NCT Number: NCT02927249
Principal Investigator: John Ayers, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Christy Kesslering, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: EAY131: Molecular Analysis for Therapy Choice (MATCH)
Clinical Trial #: EAY131
NCT Number: NCT02465060
Principal Investigator: Michael Kahn, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov

 

Study: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Clinical Trial #: NSABP B51 / RTOG1304
NCT Number: NCT01872975
Principal Investigator: Christy Kesslering, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG-022
NCT Number: N/A
Principal Investigator: John Abad, MD
Contact: Research Office 630.352.5362


Study: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609 - DART
NCT Number: NCT02834013
Principal Investigator: Christopher George, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Clinical Trial #: A221602
NCT Number: NCT03578081
Principal Investigator: Christopher George, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Kesslering
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov

Study: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Clinical Trial #: S1613
NCT Number: NCT03365882
Principal Investigator: Dr. George
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Clinical Trial #: NRG GI005
NCT Number: NCT04068103
Principal Investigator: Dr. Chawla
Contact:Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Clinical Trial #: A021703
NCT Number: NCT04094688
Principal Investigator: Dr. Dawravoo
Contact:Research Office 630.352.5362

Learn more at Clinicaltrials.gov

Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT Number: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.352.5363

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Clinical Trial #: EA2142
NCT Number: NCT02595424
Principal Investigator: Kevin Dawravoo, MD

Learn more at Clinicaltrials.gov

Study: Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck Cancer
Clinical Trial #: MDACC
Principal Investigator: Dr. Mohammed

Renal

Study: (PROSPER RCC) A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.
Clinical Trial #: EA8143
NCT Number: NCT03055013
Principal Investigator: Dr. Kahn

Learn more at Cancer.gov

Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George

Learn more at Cancer.gov

Study: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Clinical Trial #: NRG GI003
NCT Number: NCT03186898
Principal Investigator: Dr. Mohammed

Learn more at Clinicaltrials.gov


Study: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Clinical Trial #: EA5142
Principal Investigator: Linda Ferris, DO

Learn more at Clinicaltrials.gov


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG CC003
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov


Study: Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer.
Clinical Trial #: LUN005-12
Principal Investigator: John Chang, MD

Learn more at Clinicaltrials.gov


Study: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
Clinical Trial #: Protocol S1400
Principal Investigator: Linda Ferris, DO

Learn more at Clinicaltrials.gov


Study: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
Clinical Trial #: Protocol RTOG1308
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov

NCI-MATCH: Targeted Therapy Directed By Genetic Testing In Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Study: Molecular Analysis for Therapy Choice (MATCH)
Clinical Trial #: EAY131
Principal Investigator: M. Kamran Khan, DO

Learn more at Clinicaltrials.gov

 

Recurrent Tumors Previously Treated with Radiation Therapy

Study: Retreatment of non-CNS solid malignancies. Treatment sites: head & neck, thorax, pelvis, abdomen, extremities.
Clinical Trial #: UPCC 23309
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov


Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

 

Rare Tumors

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Christopher George, MD

Learn more at Clinicaltrials.gov

 

Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

 

Cross-disease sites

Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad

Study: A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Clinical Trial #: S1505
Principal Investigator: John Abad, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
Clinical Trial #: Protocol RTOG 0848
Principal Investigator: Christopher George, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Clinical Trial #: EA2142
NCT Number: NCT02595424
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Clinical Trial #: EA2185
NCT Number: NCT04239573
Principal Investigator: Dr. Chawla
Contact: Research Office 630.352.5361

Learn more at Clinicaltrials.gov

Study: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Clinical Trial #: PARTIQoL
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov


Study: (CHAARTED2) Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Clinical Trial #:EA8153
NCT Number: NCT03419234
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov


Study: (COMPPARE) A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer
Clinical Trial #: PCORI-6312
NCT Number: NCT03561220
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov


Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov


Low Risk Prostate Cancer

Study: Phase III prospective randomized trial of standard fractionation vs. hypofractionation with proton radiation therapy for low risk adenocarcinoma of the prostate.
Clinical Trial #: GU002-10
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov


Intermediate Risk Prostate Cancer

Study: Phase III study of mildly hypofractionated image guided proton beam radiation therapy with or without androgen suppression for intermediate risk adenocarcinoma of the prostate.
Clinical Trial #: GU003-10
Principal Investigator: John Chang, MD

Learn more at Clinicaltrials.gov

Ovarian

Study: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Clinical Trial #: NRG-GY005
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Ovarian

Study: A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer
Clinical Trial #: NRG-GY006
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Cervical

Study: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Clinical Trial #: GOG0263
NCT Number: NCT01101451
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Cervical

Study: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Facial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (< 2CM) Cervical Cancer
Clinical Trial #: GOG0278
NCT Number: NCT01649089
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Uterine

Study: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Clinical Trial #:GOG0238
NCT Number: NCT00492778
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Ovarian

Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Clinical Trial #: 3000-03-005
NCT Number: NCT03602859
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Ovarian or Peritoneum

Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Barbara Buttin, MD
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Current Northwestern Medicine Proton Center Clinical Trials

If you are interested in learning more about our trials, please contact your physician or visit the proton center website. If you are eligible for a proton therapy clinical trial as a patient at the Proton Center, someone from our team will likely reach out to you to communicate the details of the study.